I’ve spent the last few weeks digging deep into Plus Therapeutics’ ($PSTV) SEC filings, cross-referencing Ortex data with clinical and regulatory milestones. My goal isn’t to create "hype," but to decode the industrial logic driving management’s recent moves. What emerges is an alignment of events suggesting a vision far more comprehensive than what simple price action reflects.

1. Market Infrastructure: Diagnostics (CNSide) and Therapy (REYOBIQ)

A biotech company without reimbursement channels is a company that cannot sell. PSTV has spent the last few months building these "tracks," effectively making their assets "market-ready."

• CNSide (Liquid Biopsy): This isn't just a diagnostic test; it's the monitoring backbone for Leptomeningeal Metastases (LM). Securing the PLA code 0640U is a transformative event. This code, effective July 1, 2026, ensures the test is recognized and reimbursable by national insurance systems. Without this code, CNSide remains an experiment; with it, it becomes a revenue-generating asset.
• REYOBIQ™ (186RN Radiotherapeutic): The real challenge here is delivery into the brain via CED (Convection-Enhanced Delivery). Management secured the CPT Category III code (X566T) specifically for this procedure. Effective January 1, 2027, this perfectly aligns the surgeons' ability to be reimbursed for the procedure with the drug’s potential commercial launch window.

2. The Industrial Vision: Preparing for the "Pivotal" Trial

The news flow throughout April hasn't been random; it follows a logical sequence designed to meet FDA requirements for Accelerated Approval (AA).

• Strategic Hiring (Eric Daniels): On April 20, they brought on a new CDO (Chief Development Officer). Daniels received options with a strike price of $7.30. This sets a "baseline" for management: their incentives are tied to pushing the valuation past that threshold.
• SpectronRx Agreement (April 23): Signing a production scale-up contract while still in Phase 2 has only one meaning: the company is preparing for a registration (Pivotal) trial. The FDA requires the supply chain to be ready and GMP-validated before granting accelerated approval.
• Burn Rate Efficiency: Thanks to State Grants (such as the $17.6M from CPRIT), the company is funding a significant portion of its research with non-dilutive capital, preserving its current cash (~$20M) for commercial operations.

3. The Financial Chess Match: The $9.50 Wall

To understand where we are going, we have to look back at the "sacrifice" made in January.

• The January Offering: The company sold shares at approximately $0.38 pre-split. At the current 1:25 ratio, this corresponds exactly to $9.50. It was a painful fire sale, but it anchored the warrant strike price at the same level.
• Shorts as "Fuel": Ortex data shows a Short Interest of ~15% with a Cost to Borrow (CTB) fluctuating between 50% and 200%. Many of these short positions were opened right in the $9.50 area.
• The Technical Dynamic: The $9.50 level has become a magnet. If clinical data from ASCO pushes the price toward this threshold, shorts currently "bleeding" from the high CTB will be forced to cover (short squeeze). This forced buying pressure is the only way to break through the "wall" and allow for natural warrant exercise at full price ($9.50), providing the company with the $18-19M needed to fund Phase 3 without resorting to new discounts or "warrant inducement."

4. The Economics of Accelerated Approval (AA)

It’s often stated that a Phase 3 trial requires hundreds of millions. For PSTV, the math is different:

• With Accelerated Approval, the Pivotal trial doesn't require thousands of patients over several years; it can be based on surrogate endpoints (like the Overall Survival observed in Phase 2).
• The estimated capital needed to reach the market drops to roughly $30M. If the company nets the warrant proceeds via the short squeeze, the financial gap almost entirely closes, de-risking the roadmap toward 2027.

Summary

Everything seems to be converging on the month of May. The company has laid the tracks (reimbursement codes), secured the factory (SpectronRx), and set the challenge price at $9.50.

The dates to watch are now clear:

1. May 14-15: Lock-up expiration. Expect extreme volatility as shorts attempt to defend their positions before the clinical truth comes out.
2. May 21 (17:00 ET): ASCO Abstract Release. This is where we see if the Overall Survival (OS) data supports the Accelerated Approval thesis.
3. Late May: ASCO Annual Meeting. The moment management's "vision" must meet the reality of clinical data.

We are in a situation where financial and clinical logic have been woven together by management to force a resolution by summer. If the data is solid, the short and warrant structure will do the rest. If not, the company will have to reassess its capitalization plans. As always, the facts will speak louder than the posts.

Disclaimer: Analysis based on public SEC filings, Ortex data, and official publications. This does not constitute financial advice or a solicitation to invest. I am operating based on my own risk profile.